The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121.
French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.